Mode
Text Size
Log in / Sign up
N/A Completed N=101 Randomized Single-blind Treatment

Efficacy of T2259 in DED

Dry Eye Syndromes
Source: ClinicalTrials.gov NCT03874429 ↗
Enrolled (actual)
101
Serious AEs
1.0%
Results posted
Nov 2023
Primary outcomePrimary: Surface Ocular Staining With Fluorescein (With Oxford Scale - Ranges : 0-15) — -1.45; -1.79 score on a scale

Summary

The purpose of this study is to compare the performance and safety of T2259 versus Vismed Multi in dry eye patients with superficial keratitis.

Outcome Measures

OutcomeResultp-value
PRIMARY
Surface Ocular Staining With Fluorescein (With Oxford Scale - Ranges : 0-15)
-1.45; -1.79

Eligibility Criteria

Main inclusion Criteria:

  • Signed and dated informed consent
  • Male or female aged from ≥ 18 years old
  • Known Dry Eye Syndrome requiring artificial tears within the last 3 months prior to study selection

Main exclusion Criteria:

  • Far best-corrected visual acuity≤2/10
  • Severe Blepharitis
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03874429). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search